In this pharmacokinetic/pharmacodynamic meta-analysis, we investigated relationships between clinical endpoints and sunitinib exposure in patients with advanced solid tumors, including patients with gastrointestinal stromal tumor (GIST) and metastatic renal cell carcinoma (mRCC).
Relationship Between Exposure to Sunitinib and Efficacy and Tolerability Endpoints in Patients with Cancer: Results of a Pharmacokinetic/Pharmacodynamic Meta-analysis
2010 年 7 月 1 日
Author(s): Brett Houk, Carlo Bello, Bill Poland, Lee Rosen, George Demetri, Robert Motzer
Year: 2010 年 7 月 1 日
